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AbstrAct
Ingestion of aristolochic acid (AA) is associated with the development of aristolochic acid nephropathy, which is characterized by 
chronic renal failure, tubulointerstitial fibrosis and urothelial cancer. AA may also cause a similar type of kidney fibrosis with malignant 
transformation of the urothelium, the Balkan endemic nephropathy. Understanding which enzymes are involved in AA activation and/or 
detoxication is important in the assessment of a susceptibility to this carcinogen. The most important human enzymes activating AA by 
simple nitroreduction in vitro are hepatic and renal cytosolic NAD(P)H:quinone oxidoreductase, hepatic microsomal cytochrome P450 
1A2 and renal microsomal NADPH:cytcohrome P450 reductase, besides cyclooxygenase, which is highly expressed in urothelial tissue. 
Despite extensive research, contribution of most of these enzymes to the development of these diseases is still unknown. Hepatic 
cytochromes P450 were found to detoxicate AA in mice, and thereby protect the kidney from injury. However, which of cytochromes 
P450 are the most important in this process both in animal models and in humans have not been entirely resolved as yet. In addition, 
the relative contribution of enzymes found to activate AA to species responsible for induction of urothelial cancer in humans remains 
still to be resolved.
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Introduction
Aristolochic acid (AA), the plant extract of Aristolochia spe-
cies, is a mixture of structurally related nitrophenanthrene 
carboxylic acids, with 8-methoxy-6-nitro-phenanthro-(3,4-
d)-1,3-dioxolo-5-carboxylic acid (AAI) and 6-nitro-phenan-
thro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAII), being the 
major components (Figure 1) (IARC, 2002). Recently AA 
was proven to be the cause of so-called Chinese herbs neph-
ropathy (CHN), a unique type of rapidly progressive renal 
fibrosis associated with the prolonged intake of Chinese 
herbal remedies during a slimming regimen, observed for 
the first time in Belgium in 1991 (Vanherweghem et al., 
1993; Vanhaelen et al., 1994; Schmeiser et al., 1996). About 
100 CHN cases have been identified so far in Belgium, half 
of which needed renal replacement therapy, mostly includ-
ing renal transplantation (Arlt et al., 2002b). The observed 
nephrotoxicity has been traced to the ingestion of herbal 
preparation Aristolochia fangchi containing nephrotoxic AA 
inadvertently included in slimming pills (Vanhaelen et al., 
1994). CHN patients, who were exposed to Aristolochia spe-
cies containing AA and had no relationship with the Belgian 
slimming clinic, have been identified in other European 
countries, in Asia and in the USA (about 170 cases) (Arlt 
et al., 2002b). Therefore, this disease is now called aristo-
lochic acid nephropathy (AAN) (Gillerot et al., 2001; Arlt 
et al., 2002b; Cosyns, 2003). Recently, a high prevalence of 
urothelial cancer was found in the cohort of AAN patients 
in Belgium (Nortier et al., 2000) and cases of urothelial can-
cer have also been described in other countries (Arlt et al., 
2004). These findings highlight the carcinogenic potential 
of AA to humans. Indeed, AA is among the most potent 2% 
of known carcinogens (Arlt et al., 2002b; IARC, 2002). As 
a consequence, herbal remedies containing species of the 
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genus Aristolochia were recently classified as carcinogenic 
to  humans  (Group  1)  by  the  International  Agency  for 
Research on Cancer (IARC) (IARC, 2002).
It  is  also  noteworthy  that  AA  consumption  may  be 
a cause for the development of a similar type of kidney 
fibrosis with malignant transformation of the urothelium, 
the Balkan endemic nephropathy (BEN) (Ivic, 1969; Tatu et 
al., 1998; Arlt et al., 2002a; Stiborová et al., 2005b), which is 
widely found in certain areas of Romania, Croatia, Bosnia, 
Serbia and Bulgaria along the Danube river basin (Tatu et 
al., 1998; Stiborová et al., 2005b; Stefanovic et al., 2006). At 
least 25,000 individuals suffer from BEN or are suspected 
of having the disease, while the total number of people at 
risk in these countries may exceed 100,000. Although first 
described more than 50 years ago, the etiology of BEN 
remains unclear and is a matter of debate (Tatu et al., 1998; 
Stefanovic et al., 2006). For the last years evidence has 
accumulated that BEN is an environmental disease. Recent 
experimental data shows that AA might be one of the most 
important etiologic factors in BEN and associated urothelial 
cancer (Arlt et al., 2002a; Stefanovic et al., 2006; Grollman 
et al., 2007). AA exposure is associated with chronic dietary 
uptake of seeds of Aristolochia clematitis by the population 
living in BEN regions (Ivic, 1969; Arlt et al., 2002a; Hranjec 
et al., 2005).
Aristolochic Acid-Mediated Renal 
Injury and Carcinogenesis 
The molecular mechanisms for AA-mediated renal injury, 
and if it is an early stage of the urothelial-specific tumor 
development, are still matter of debate and need further 
investigations.  In  this  context,  it  is  noteworthy  that  a 
case  of  AA-induced  tumor  development  without  renal 
injury (Nortier et al., 2003) suggests dissociation between 
AA-mediated nephrotoxicity and carcinogenicity. AA seems 
to directly cause renal injury through activating mitochon-
drial permeability transition, which was found recently in 
human renal tubular epithelial cells (Qi et al., 2007). This 
suggestion, however, needs to be confirmed by further stud-
ies. In contrast to suggestion that AA might be the direct 
cause of the instestitial nephropathy, metabolic activation 
of AA to species forming DNA adducts is an important step 
for AA-induced malignant transformation (Arlt et al., 2007; 
Stiborová et al., 2008b). Indeed, the molecular mechanism of 
AA-induced carcinogenesis demonstrates a strong associa-
tion between DNA adduct formation, mutation pattern and 
tumour development (Arlt et al., 2007). The predominant 
AA-DNA adduct, 7-(deoxyadenosin-N6-yl)aristolactam I 
(dA-AAI), which is the most persistent of the adducts in the 
target tissue, is a mutagenic lesion leading to AT trans-
versions in the p53 gene in DNA from urothelial tumors of 
AAN and BEN patients (Lord et al., 2004; Arlt et al., 2007; 
Grollman et al., 2007). 
Metabolism of Aristolochic Acid and 
Biotransformation Enzymes 
One of the common features of AAN and BEN is that not 
all individuals exposed to AA suffer from nephropathy 
and tumor development. We have suggested earlier that 
one cause for these different responses may be individual 
differences in the activities of the enzymes catalyzing the 
biotransformation (detoxication and/or activation) of AA 
(for a summary, see Stiborová et al., 2008b) Many genes of 
enzymes metabolizing toxicants and carcinogens are known 
to exist in variant forms or show polymorphisms resulting 
in differing activities of the gene products. These genetic 
variations appear to be important determinants of cancer 
risk or other toxic effects of xenobiotics (Stiborová et al., 
2008b). 
The proposed activation and detoxication pathways for the 
major component of AA, aristolochic acid I (AAI), are shown 
in the Figure 2. AAI is activated by simple nitroreduction to 
N-hydroxyaristolactam I that forms a cyclic N-acylnitrenium 
ion as the ultimate carcinogenic species binding to DNA 
to form 7-(deoxyadenosin-N6-yl)aristolactam I (dA-AAI) 
as the major persistent adduct, participating in initiation 
of carcinogenesis. The enzymes activating AA to species 
binding to DNA in vitro were studied in details (Stiborová 
et al., 2008b). Using in vitro studies we have found that the 
most important human and rat enzyme activating AAI in 
vitro in hepatic and renal cytosolic subcellular fractions is 
NAD(P)H:quinone oxidoreductase (NQO1)(Stiborová et al., 
2002a; 2003; 2005a) followed by cytochrome P450 (CYP) 
1A1/2 in liver microsomes (Stiborová et al., 2001c; 2005c) 
and NADPH:CYP reductase (POR) in kidney microsomes 
(Stiborová et al., 2001b; 2005a), besides prostaglandin H 
synthase (cyclooxygenase, COX) (Stiborová et al., 2001a), 
which is highly expressed in urothelial tissue. However, the 
confirmation that isolated (purified) human NQO1 is really 
capable of activating AAI remains still to be investigated. 
Such a proof is of great importance. It is namely noteworthy 
that  NQO1-polymorphism  (the  genotype  NQO1*2/*2) 
seems to predispose patients suffering from BEN to the 
development of urothelial malignancy of the upper uri-
nary tract (OR=13.75, 95%CI 1.17-166.21) (Toncheva et al., 
2004). Therefore, the targets of our future work are the 
confirmation of this finding (predisposition of patients to 
the development of cancer by NQO1-polymorphism), and 
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the confirmation of the major role NQO1 in AAI activation. 
The results of such studies might answer the question why 
AAI-induced cancer is developed in only some of the AAN 
and BEN patients.
The competing conversion of N-hydroxyaristolactam I 
to the corresponding 7-hydroxyaristolactam or its further 
reduction to aristolactam I should be considered detoxica-
tion pathway; both these metabolites were found to be 
excreted. However, even though aristolactam I is not a direct 
DNA binding species, low amounts of the dA-AAI adduct, 
with the highest levels in one of the target tissues, the renal 
pelvis, were generated in rats treated with aristolactam I 
(Dong et al., 2006). This result is consistent with finding 
that formation of the dA-AAI adduct by aristolactam I 
was observed after its in vitro activation with different 
peroxidases of which several, such as COX-1 and/or COX-2, 
are expressed at high levels in renal tissue (Stiborová et 
al.,  1999).  It  is  still  questionable  if  enzymes  capable  of 
conjugating the proximate carcinogenic metabolite of AAI, 
N-hydroxyaristolactam I, are involved in AAI activation. 
Meinl et al. (2006) demonstrated that expression of some 
human sulfotransferases (SULTs), particularly SULT1A1, in 
bacterial and mammalian target cells enhances the muta-
genic activity of AAI. However, our preliminary experi-
ments did not bring unambiguous results. On one hand, we 
found that an increase in AAI-induced mutagenicity was 
correlated with higher AAI-DNA adduct levels in V79 cells 
transfected with human SULT1A1 (Glatt et al., unpublished 
results). However, our further results suggest that SULTs in 
human hepatic and renal cytosols do not participate in an 
increase in AAI-DNA adduct formation in these subcellular 
systems. Thus, the exact role of conjugation enzymes in 
AAI activation awaits further investigation and is another 
aim of our additional studies. 
While most of the enzymes catalyzing the reductive 
activation of AAI in vitro have already been identified, 
the question, which of them actually participates in this 
process in vivo, remains to be answered. Additional factors 
such as route of administration, absorption, renal clearance 
and tissue-specific enzyme expression make it difficult to 
extrapolate from data found in vitro (Stiborová et al., 2008b) 
to the in vivo situation. Such a study is, therefore, the next 
target of our future investigation.
The oxidation of AAI to aristolochic acid Ia (AAIa) 
has been suggested to be a detoxication pathway of AAI 
(Arlt et al., 2002b; Stiborová et al., 2008b). Namely, AAIa 
or its conjugates, the O-glucuronide, the O-acetate and the 
O–sulfate esters, were excreted in urine (Chan et al., 2006; 
2007). AAIa is also reduced to N-hydroxyaristolactam Ia 
forming aristolactam Ia, which together with its conjugates, 
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induced by MC, could contribute to decreased AAI levels 
in MC-treated mice. 
Taking into account all data known at the present time, 
we propose that the pathways of AAI metabolism are dic-
tated by the binding affinity of AAI to CYP1A or NQO1, and 
their enzymatic turnover as well as by the balance between 
the efficiency of CYP1A to oxidize and reduce AAI. In order 
to confirm this assumption and to complement our former 
studies (Stiborová et al., 2008b; 2008c), and the work of Xiao 
et al. (2008), we started a study investigating formation of 
AAI-DNA adducts in the HRN mouse model, and in models, 
in which CYP1A genes are deleted.
Conclusions
Although hepatic CYP enzymes were found to detoxicate 
AAI in mice, thus decreasing its renal toxicity (Xiao et al., 
2008), individual enzymes, which might metabolize (activate 
and/or detoxicate) AAI in vivo, and their impact on AAI-
mediated nephrotoxicity and carcinogenicity, have not been 
fully resolved as yet. Therefore, such a subject remains to 
be investigated. Namely, the evaluation of inter-individual 
variations in the human enzymes playing a major role in 
AAI activation and detoxication, including their genetic 
polymorphisms, remain a major challenge to explain an 
individual’s susceptibility to AAI, and to predict cancer risk 
among the AAN and BEN patients. Therefore, the study we 
started in our laboratory addresses still unsettled question 
whether the metabolism of AAI, and if so, which enzymes 
participating in this process, determine pathophysiological 
effects of this compound in development of AAN and BEN 
diseases. 
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the N- and O-glucuronides, is excreted (Chan et al., 2006; 
2007). Enzymatic reactions leading to aristolactam Ia and its 
metabolites seem to be purely detoxication pathway, because 
DNA adducts containing aristolactam Ia structure have as 
yet never been found. In contrast to the enzymes activating 
AAI in vitro, those participating in AAI oxidation to AAIa 
both in vitro and in vivo have not been extensively studied 
so far. Our preliminary studies indicated that CYP enzymes 
can generate this oxidative metabolite (Stiborová et al., 
2008b). However, the question which of the CYP enzymes 
are responsible for formation of AAIa remains still to be 
investigated. In this context it is noteworthy that a large-
scale investigation in BEN patients on the role of genetic 
polymorphisms in genes of some phase I detoxication CYP 
enzymes revealed a possible risk for BEN (OR 2.41) in indi-
viduals carrying CYP3A5*1 allele G6989 (Toncheva et al., 
2004; Toncheva 2006). Although we found that this CYP did 
not activate AAI to dA-AAI adduct (Stiborová, unpublished 
results), we do not know, if this CYP species is involved in 
AA detoxication. Furthermore, as mentioned above, we also 
do not know if other CYPs, and which of them, are capable of 
detoxicating AAI. Therefore, the evaluation of the oxidative 
detoxication of AAI by individual CYP enzymes is the target 
of studies in several laboratories. Indeed, very recently, Xiao 
et al. (2008) showed novel data concerning the enzymes 
detoxicating AAI. The HRN (Hepatic Cytochrome P450 
Reductase Null) mice, which we had shown previously to be 
a suitable model to determine hepatic xenobiotic metabo-
lism in vivo (Arlt et al., 2005; 2006; 2008; Stiborová et al., 
2008a) and suggested to use to elucidate AA metabolism 
(Stiborová et al., 2008b), were successfully used in their 
study (Xiao et al., 2008). The authors’ results indicate that 
hepatic CYPs detoxify AAI by its demethylation to aristo-
lochic acid Ia (AAIa), and thereby protect the kidney from 
AAI-induced injury. The observations of Xiao et al. (2008) 
combined with results found previously, support strongly 
the former hypothesis (Stiborová et al., 2008b) that a key 
point determining the carcinogenic and nephrotoxic effects 
of AAI lies in the balance of activities of reductases such 
as NQO1, catalyzing the AAI-DNA adduct formation, and 
enzymes such as CYPs, which detoxicate AAI to AAIa.
The question which of the CYP enzymes are responsible 
for formation of AAIa remains still to be investigated. The 
in vitro experiments of Xiao et al. (2008) indicate that CYP1A 
generate AAIa. However, the model used to evaluate CYP1A 
participation in formation of AAIa in vivo, mice treated with 
an inducer of CYP1A 3-methycholanthrene (MC), did not 
bring unambiguous results. Namely, MC also induces other 
enzymes beside CYP1A. Although treatment of mice with 
MC leads to decrease in AAI concentrations in the liver and 
kidney, no increase in AAIa concentrations was found in 
the liver, only in the kidney of mice treated with the higher 
dose of AAI (20 mg/kg). An increase in AAIa excretion due 
to its conjugation with glucuronide, caused by induction 
of  UDP-glucuronosyltransferase  with  MC,  could  occur. 
Nevertheless, because CYP1A enzymes also activate AAI to 
species forming DNA adducts (Stiborová et al., 2008b), the 
decrease of AAI in liver and kidney might also result from 
this reaction. Moreover, NQO1, which is also efficiently 
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